Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma

Abstract

Zanubrutinib was associated with lower 90-day switching rates and estimated proportion of patients receiving next line of therapy at 180 days vs acalabrutinib and ibrutinib in 1L and 2L.